Technique improves drug delivery system characterization

16 Mar 2020

Postnova Analytics' CF2000 Centrifugal Field Flow Fractionation (CF3) system is delivering exciting new data to scientists developing drug delivery systems.

The determination of cargo mass per delivery vesicle is one of the big challenges of characterization of any drug delivery system. Size characterization techniques are inherently inadequate to provide such information. By comparison, Postnova Analytics has found that its CF2000 CF3 system, a mass-based, high-resolution separation instrument, is capable of measuring the cargo mass per vesicle to a limit of quantification of 12 attogram (12 x 10-18 g).

Technique improves drug delivery system characterization

In CF3, the separation force is established by a centrifugal field, which is generated by spinning the complete circular channel at a high rate. The bigger and denser particles are forced more in the direction of the outer wall than the smaller particles. As a consequence, bigger particles are eluted later from the CF3 channel as they are located in slower streamlines in the channel than the smaller particles which are located in faster streamlines.

Based on the CF3 principle, the Postnova CF2000 employs a centrifugal field as the driving force for separations. Particles affected by this field are separated by dynamic diffusion on the basis of both particle size and density. This unique feature of the CF2000 allows the separation of different particulate materials having the same particle size.

Separations on the CF2000 can be further optimized by using different eluents and temperature programs. As a consequence, the CF2000 system is proving an ideal tool for the separation and characterization of complex particulate samples in areas including pharmaceutical drug delivery systems.

In contrast to traditional particle sizing techniques, which work in the batch mode, the CF3 technique physically separates each particle fraction prior to sizing. This avoids numerous disadvantages of these batch techniques such as low size resolution, discrimination and under estimation of smaller compared to larger particles.

Using Postnova CF3 technology bypasses the necessity for special sample preparation as they can be injected directly without filtration, allowing the characterization of even complex particulate materials without alteration and damage.

Related news

New blood test able to detect 50 cancer types

New blood test able to detect 50 cancer types

31 Mar 2020

Study data support blood test's ability to detect 50 types of cancer and identify where in the body the cancer is located.

Read more 
European patent granted for amatoxin conjugates for tumor therapy

European patent granted for amatoxin conjugates for tumor therapy

31 Mar 2020

The patent covers the crosslinking of certain carrier molecules, for example, antibodies, via specific binding sites to amatoxins.

Read more 
ProBioGen selected for development and large-scale manufacturing services

ProBioGen selected for development and large-scale manufacturing services

24 Mar 2020

The Contract Development and Manufacturing Organization (CDMO) and technology provider will use its CHO.RiGHT expression platform for high-titer cell line development.

Read more 
Positive update on the development of new XF‐platform drug formulations

Positive update on the development of new XF‐platform drug formulations

24 Mar 2020

Collaboration with MedPharm delivers data profiling new XF‐platform drug formulations as potential treatments for dermal and ocular infections.

Read more 
Alvotech and DKSH partner to bring key biosimilar to Asia

Alvotech and DKSH partner to bring key biosimilar to Asia

24 Mar 2020

Together, the companies will provide APAC markets with a cost-effective alternative to the largest-selling blockbuster medicine worldwide.

Read more 
Codexis and Takeda collaborate to advance novel gene therapies

Codexis and Takeda collaborate to advance novel gene therapies

23 Mar 2020

Partnership to leverage Codexis’ protein engineering platform for the discovery and development of novel transgenes for lysosomal storage disorders and blood factor deficiencies.

Read more 
Vaxxas HD-MAP to deliver vaccines directly to the skin

Vaxxas HD-MAP to deliver vaccines directly to the skin

17 Mar 2020

Company awarded US$5 million grant for clinical study of measles and rubella vaccination using Vaxxas’ high-density, micro-array patch.

Read more 
Regeneron and Sanofi begin global Kevzara clinical trial program in patients with severe COVID-19

Regeneron and Sanofi begin global Kevzara clinical trial program in patients with severe COVID-19

16 Mar 2020

The trial is the first controlled trial in the US to evaluate the effect of IL-6 inhibition prospectively in COVID-19 patients.

Read more 
Nanoform and Orion collaborate on 'nanoformed' APIs

Nanoform and Orion collaborate on 'nanoformed' APIs

9 Mar 2020

Active pharmaceutical ingredients (APIs) nanoformed using the CESS process demonstrate promise for overcoming solubility and bioavailability challenges.

Read more 
Bristol Myers Squibb disappointed with failed late-stage combo drug trial

Bristol Myers Squibb "disappointed" with failed late-stage combo drug trial

9 Mar 2020

Phase III study evaluating Empliciti plus Revlimid and dexamethasone in patients with newly diagnosed, untreated multiple myeloma fails to meet primary endpoint.

Read more